Pulmonary Arterial Hypertension Market

Mar 2021| MRS128A| Market Research Studies

Report Highlights

The scope of this report covers the different drug classed used to treat pulmonary arterial hypertension along with the probable novel therapies used to cure the disease. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug class, route of administration, distribution channel, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional pulmonary arterial hypertension markets; it explains the major market drivers of the global pulmonary arterial hypertension industry, current trends within the industry, major applications, and the regional dynamics of the global pulmonary Arterial Hypertension Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global pulmonary arterial hypertension market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

  • 35 tables and 43 figures
  • An up-to-date analysis of the Global Pulmonary Arterial Hypertension Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Pulmonary Arterial Hypertension Market, and corresponding market share analysis by drug class, route of administration, distribution channel, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Pulmonary Arterial Hypertension, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Pulmonary Arterial Hypertension Market as compared to overall global economy.
  • Insight into the growth development strategies of major Pulmonary Arterial Hypertension manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, Johnson & Johnson, Bayer AG, Pfizer, Inc., GlaxoSmithKline Plc., United Therapeutics Corporation, Gilead Sciences, Inc., and others.

Summary

Pulmonary Arterial Hypertension mainly known as pulmonary hypertension is a rare disease in which there is an increase of the blood pressure in the lungs. The disease could lead to localized hypertension or pulmonary arterial pressure which would ultimately lead to heart failure. Some of the key factors involved in the growth of pulmonary arterial hypertension market is increasing government activities for the manufacturing and usage of orphan drugs, rising geriatric population, and increasing prevalence of pulmonary arterial hypertension.

The World Health Organization (WHO) states that the population of people over the age of 60 years will almost double from 12 to 22% in between 2015 and 2050. The symptoms of pulmonary arterial hypertension include chest pain, shortness of breath, and fainting. The technological innovations are also progressively focused for the identification and development of better treatment measures during the forecast. Furthermore, emergence of new companies would also create lucrative opportunities for the growth of global pulmonary arterial hypertension market during the forecast period. The pulmonary arterial hypertension could be treated by various drug class such as, prostacyclin and prostacyclin analogs, SGC stimulators, endothelin receptor antagonists, phosphodiesterase 5, and many others.

The Global Pulmonary Arterial Hypertension Market was valued at $6.74 billion in 2020 and is expected to witness a steady growth at a CAGR of 6.18%

  • Table 1 : Global Pulmonary Arterial Hypertension Market, Through 2026
  • Table 2 : Global Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 3 : Global Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 4 : Global Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 5 : Global Pulmonary Arterial Hypertension Market, by Region, Through 2026
  • Table 6 : North America Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 7 : North America Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 8 : North America Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 9 : North America Pulmonary Arterial Hypertension Market, by Country, Through 2026
  • Table 10 : Europe Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 11 : Europe Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 12 : Europe Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 13 : Europe Pulmonary Arterial Hypertension Market, by Country, Through 2026
  • Table 14 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 15 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 16 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 17 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Country, Through 2026
  • Table 18 : South America Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 19 : South America Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 20 : South America Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 21 : South America Pulmonary Arterial Hypertension Market, by Country, Through 2026
  • Table 22 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
  • Table 23 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
  • Table 24 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
  • Table 25 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Country, Through 2026
  • Table 26 : Johnson & Johnson: Financial Performance, Through 2020
  • Table 27 : Bayer AG: Financial Performance, Through 2020
  • Table 28 : Pfizer, Inc.: Financial Performance, Through 2020
  • Table 29 : GlaxoSmithKline Plc.: Financial Performance, Through 2020
  • Table 30 : United Therapeutics Corporation: Financial Performance, Through 2020
  • Table 31 : Gilead Sciences, Inc.: Financial Performance, Through 2020
  • Table 32 : Bristol-Myers Squibb Company: Financial Performance, Through 2020
  • Table 33 : Merck & Co. Inc.: Financial Performance, Through 2020
  • Table 34 : Daiichi Sankyo Company Limited: Financial Performance, Through 2020
  • Table 35 : Eli Lilly and Company: Financial Performance, Through 2020
  • Figure 1 : Global Pulmonary Arterial Hypertension Market
  • Figure 2 : Global Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 3 : Global Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 4 : Global Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 5 : Global Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 6 : Global Pulmonary Arterial Hypertension Market, by Value, by Region, 2020
  • Figure 7 : Global Pulmonary Arterial Hypertension Market, by Value, by Company, 2020
  • Figure 8 : Global Pulmonary Arterial Hypertension Market, Product Map, 2020
  • Figure 9 : North America Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 10 : North America Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 11 : North America Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 12 : North America Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 13 : North America Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
  • Figure 14 : Europe Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 15 : Europe Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 16 : Europe Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 17 : Europe Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 18 : Europe Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 21 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 22 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 23 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
  • Figure 24 : South America Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 25 : South America Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 26 : South America Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 27 : South America Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 28 : South America Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
  • Figure 31 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
  • Figure 32 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
  • Figure 33 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
  • Figure 34 : Johnson & Johnson: Revenue Share, 2020
  • Figure 35 : Bayer AG: Revenue Share, 2020
  • Figure 36 : Pfizer, Inc.: Revenue Share, 2020
  • Figure 37 : GlaxoSmithKline Plc.: Revenue Share, 2020
  • Figure 38 : United Therapeutics Corporation: Revenue Share, 2020
  • Figure 39 : Gilead Sciences, Inc.: Revenue Share, 2020
  • Figure 40 : Bristol-Myers Squibb Company: Revenue Share, 2020
  • Figure 41 : Merck & Co. Inc.: Revenue Share, 2020
  • Figure 42 : Daiichi Sankyo Company Limited: Revenue Share, 2020
  • Figure 43 : Eli Lilly and Company: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report